The promise of novel FolRα-targeting antibody : vimars

Presented today by VHIO’s Ana Oaknin at the 2023 ASCO Annual Meeting, 2-6 June (Chicago, IL), updated dose expansion data of the STRO-002-GM1 global phase I study show promise of FolRα-targeting antibody drug conjugate (ADC) luveltamab tazevibulin in patients with recurrent FolRα-expressing epithelial ovarian cancer.

Related Keywords

Hebron , Israel General , Israel , Madrid , Spain , United States , Chicago , Illinois , American , Craig Berman , Hatem Dokainish , David Omalley , Lin Liu , Carmen Garc , Lainie Martin , John Diaz , Jesus Garcia , Alexander Spira , Russell Schilder , Michael Palumbo , Christina Annunziata , Denise Uyar , Tanja Pejovic , John Moroney , Caixa Foundation , Hebron Institute Of Oncology , Severo Ochoa Center , Gynecological Malignancies Group , Research Centres Of Catalonia , Hebron University Hospital , Ana Oaknin , Principal Investigator , Hebron Institute , American Society , Clinical Oncology , Medical Oncologist , Lorena Fari , Davido Malley , Jesus Garcia Donas , Oral Abstract , Hebron Campus , Research Centres ,